Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx zahraničních xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. a x. 46/2008 Xx. x. s. x xxxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 97/2012 Xx. m. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx dne 12. xxxxxxxxx 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek a xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx1).
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Parlament Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. ledna 2013 x xxxxx dnem xxxxxxxxx x xxxxxxxx x pro Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x platnost xxxxxxxx platit xxxxx Xxxxxxx I Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx platné xx 1. ledna 2012 x xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Anglické xxxxx Xxxxxxx X x xxxx xxxxxxx xx českého jazyka xx vyhlašují xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx xxxxxxx xxx 19. října 2005 x Paříži xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX X
XXXXXX ZAKÁZANÝCH LÁTEK X METOD DOPINGU XXX XXX 2013
XXXXXXX ANTIDOPINGOVÝ XXXXX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx látek xx xxxxxx S1, X2, S4.4, X4.5 x S6(a) a Xxxxxxxxxx xxxxx X1, X2 a X3.
| &xxxx;
XXXXX X XXXXXX XXXXXXXX XXXXX
(PŘI XXXXXXX X MIMO XXXXXX)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (např. léčiva x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx stále.
S1. XXXXXXXXXX LÁTKY
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):
(a) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (estr-4-en-3β,17β-diol); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); methyldienolon (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx podány exogenně:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x jejich xxxxxxxxxx a xxxxxxx, xxx xx s xxxxxxxx pouze na xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
|
|
5α-androstan-3α,17β-diol
|
|
|
5α-androstan-3β,17α-diol
|
epi-dihydrotestosteron
|
|
5α-androstan-3β,17β-diol
|
epitestosteron
|
|
androst-4-en-3α,17α-diol
|
3α-hydroxy-5αandrostan-17-on
|
|
androst-4-en-3α,17β-diol
|
3β-hydroxy-5αandrostan-17-on
|
|
androst-5-en-3β,17α-diol
|
7α-hydroxy-DHEA
|
|
androst-5-en-3α,17α-diol
|
7β-hydroxy-DHEA
|
|
androst-5-en-3α,17β-dioI
|
7-keto-DHEA
|
|
androst-5-en-3β,17α-diol
|
19-norandrosteron
|
|
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x xxxxxxxx xxxxx xx ně.
|
Pro xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx vztahuje k xxxxx, xxxxxx tělo xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx x látce, xxxxxx xxxx xxxx xxxxxxxxxx přirozeně.
|
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX XXXXX
Následující xxxxx a jejich xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (např. xxxxxxxxxxxx (EPO), darbepoetin (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (HIF), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx hormon (XX) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (GH), fibroblastové xxxxxxx faktory (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx xxxxxxx faktory (XXX), xxxxxxx xxxxxx xxxxxxxx z krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx růstové xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, krevní zásobení, xxxxxxx xxxxxxx, regenerativní xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Všichni xxxx-2 agonisté xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. d- x x-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (maximálně 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx s xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx než 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx x koncentraci vyšší xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx pozitivní laboratorní xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl způsoben xxxxxxxx xxxxxxxxxxxx inhalační xxxxx xxxxx xxx xxxx uvedené xxxxxxx.
X4. XXXXXXXXX A XXXXXXXXXXX MODULÁTORY
Xxxxxxxx xx následující:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, anastrozol, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, testolacton, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, toremifen, xxx xx x omezením xxxxx xx ně.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx s omezením xxxxx na xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx proliferátory /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Receptor δ (XXXXδ) agonists/ (xxxx. GW 1516) x Agonisté xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x součinnosti s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (XXXX) xxxx agonists/ (xxxx. XXXXX)
S5. DIURETIKA X XXXXXXX XXXXXXXXX XXXXX
Maskovací xxxxx xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, desmopressin, plasmaexpandery (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s podobnými xxxxxxxxxxxx účinky. Lokální xxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, chlortalidon, indapamid, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren x xxxxx látky s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Xxx použití (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx prahovým xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx xxxx jinou xxxxxxxxx látkou xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxx xxxx znovuzavedení xxxxxxxxx, homologní xxxx xxxxxxxxxxx xxxx nebo xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx nebo xxxxxxx xxxxxxx, zahrnující modifikované xxxxxxxxxxxxx produkty (např.krevní xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx pouze xx ně. Xxxxxxxxxxxx xxxxxxxx zakázána xxxx.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx s xxxx nebo x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ X XXXXXXXXX MANIPULACE
Xxxxxxxx xx následující:
1. Xxxxxxxxx, xxxx pokus x xxxxxx, xx xxxxxx xxxxxxx integritu x platnost Xxxxxx xxxxxxxxxx při Dopingové xxxxxxxx je zakázané. Xx zahrnuje xxxxxx x/xxxx úpravu (např. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx na xx.
2. Nitrožilní infuze x/xxxx injekce xxxx xxx 50 ml xx 6 hodin xxxx xxxxxxxx kromě xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
M3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx sportovního xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx nukleových xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
| &xxxx;
LÁTKY X XXXXXX ZAKÁZANÉ XXX SOUTĚŽI
|
Xxxxx kategorií X0 xx X5 x X1 xx M3 xxxxxxxxx výše jsou Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx jejich xxxxxxxxxx optických xxxxxxx (xxxx. x- x x-) jsou xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx místního xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx zahrnují:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, amfetaminil, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, famprofazon, fendimetrazin, xxxxxxxxx, fenfluramin, xxxxxxxx, xxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (d-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, které xxxx xxxxxxxx uvedeno x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, metylefedrin****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (dimetylpentylamin), niketamid, xxxxxxxxxxx, oktopamin, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Lokální podání xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) nebo xxxx podání společně x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx je xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx moči.
**** Xxxxxxx a xxxxxxxxxxxxx xxxx zakázány při xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.
***** Pseudoefedrin je xxxxxxx, pokud xxxx xxxxxxxxxxx x xxxx xx vyšší xxx 150 xxxxxxxxxx xx xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx a jeho xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
S8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx a xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, XXX073/ x XX-210) xxxx xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Všechny xxxxxxxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X URČITÝCH XXXXXXXX
|
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Xxx Xxxxxxx v následujících xxxxxxxx. Detekce xx xxxx xxxxxxxx dechovou xxxxxxxx x/xxxx rozborem xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická hodnota) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a parašutismus(FAI)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx zakázány xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Mimo xxxxxx)
∙ Lyžování (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x snowboard X-xxxxx x "xxx xxx"
∙ Xxxxxxx (XXXX, XXX) (zakázané také Xxxx xxxxxx)
∙ Xxxxx (WDF)
Beta-blokátory xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, esmolol, karteolol, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx s omezením xxxxx na xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. nabyl účinnosti xxxx 20.12.2013.
Xxxxxx xxxxxxx č. 98/2013 Xx. x. x. xxx zrušen právním xxxxxxxxx č. 47/2014 Sb. m. s. x xxxxxxxxx od 20.9.2014.
Znění jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx právního xxxxxxxx.